{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:37:13Z","timestamp":1761647833697,"version":"3.38.0"},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T00:00:00Z","timestamp":1300665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this cross\u2010over study was to compare clindamycin pharmacokinetics in the serum of clinically normal dogs when administered orally at two dosage regimens (5.5\u2003mg\/kg, twice daily, and 11\u2003mg\/kg, once daily), separated by a 1\u2003week wash\u2010out period. Serum samples were obtained from six clinically normal laboratory beagles before, 3, 6, 9 and 12\u2003h after the first and fifth dose of clindamycin at 5.5\u2003mg\/kg, twice daily, and before, 3, 6, 9, 12, 18 and 24\u2003h after the first and third dose at 11\u2003mg\/kg, once daily. Serum clindamycin concentrations were determined by reverse\u2010phase liquid chromatography coupled with mass spectrometry. Results were analysed using Student\u2019s paired<jats:italic>t<\/jats:italic>\u2010test, at a 5% level of significance. Values of pharmacokinetic parameters that differed significantly between the two dosage regimens included the following: maximal concentration and area under the concentration\u2013time curve were higher at 11\u2003mg\/kg, once daily, than at 5.5\u2003mg\/kg, twice daily; and, more importantly, the ratio of AUC<jats:sub>0\u201324<\/jats:sub>to the minimal inhibitory concentration (MIC) value of 0.5\u2003\u03bcg\/mL for a 24\u2003h period (AUC<jats:sub>0\u201324<\/jats:sub>\/MIC) was higher when clindamycin was administered at 11 than at 5.5\u2003mg\/kg, at least during the first day of drug administration. Therefore, a better pharmacokinetic profile may be expected when clindamycin is administered at 11\u2003mg\/kg, once daily, for the treatment of canine pyoderma caused by<jats:italic>Staphylococcus pseudintermedius<\/jats:italic>.<\/jats:p>","DOI":"10.1111\/j.1365-3164.2011.00969.x","type":"journal-article","created":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T18:14:56Z","timestamp":1300731296000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Serum pharmacokinetics of clindamycin hydrochloride in normal dogs when administered at two dosage regimens"],"prefix":"10.1111","volume":"22","author":[{"given":"Manolis N.","family":"Saridomichelakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Labrini V.","family":"Athanasiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Salame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manolis K.","family":"Chatzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Katsoudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis S.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/vr.151.20.600"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/vr.132.14.351"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.5326\/0380407"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0450.2005.00836.x"},{"key":"e_1_2_5_6_2","first-page":"560","article-title":"Staphyococcal pyoderma: an emerging problem","volume":"26","author":"Hnilica KA","year":"2004","journal-title":"Compendium of Continuing Education for the Practicing Veterinarian"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2006.04.004"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00360-07"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01150-07"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00893.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00828.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-7216-7618-0.50008-0"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3164.1999.00176.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.5326\/15473317-37-6-537"},{"key":"e_1_2_5_15_2","first-page":"753","article-title":"Efficacy of clindamycin hydrochloride capsules for the treatment of deep pyoderma due to Staphylococcus intermedius infection in dogs","volume":"39","author":"Scott DW","year":"1998","journal-title":"Canadian Veterinary Journal"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0450.2004.00816.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0147-9571(97)00026-X"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00366918"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2460\/ajvr.1986.47.02.229","article-title":"Frequency and antimicrobial susceptibility of Staphylococus species isolated from canine pyodermas","volume":"47","author":"Medleau L","year":"1986","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.1992.tb00147.x"},{"issue":"1","key":"e_1_2_5_21_2","first-page":"30","article-title":"Kinetics of antibacterial activity after administration of enrofloxacin in dog serum and skin: in vitro susceptibility of field isolates","volume":"18","author":"Stegemann M","year":"1996","journal-title":"Compendium of Continuing Education for the Practicing Veterinarian"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.12681\/jhvms.15388","article-title":"Antibiotic resistance of Staphylococcus intermedius strains isolated from 53 natural cases of canine pyoderma","volume":"53","author":"Saridomichelakis MN","year":"2002","journal-title":"Bulletin of the Hellenic Veterinary Medical Society"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/vr.144.24.662"},{"key":"e_1_2_5_24_2","first-page":"409","volume-title":"Pharmacokinetics: Principles and Applications","author":"Welling PG","year":"1987"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2460\/javma.1989.195.01.124","article-title":"Pharmacologic features of clindamycin in dogs and cats","volume":"195","author":"Harari J","year":"1989","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_5_27_2","first-page":"18","volume-title":"Small Animal Clinical Pharmacology and Therapeutics","author":"Boothe DM","year":"2001"},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2460\/javma.1980.176.10.1072","article-title":"Pharmacotherapeutics of macrolides, lincomycins, and spectinomycin","volume":"176","author":"Burrows GE","year":"1980","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.1997.00047.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2004.06.007"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.1999.00221.x"},{"issue":"1","key":"e_1_2_5_32_2","article-title":"Oral absorption, bioavailability and tolerance study of clindamycin gel 3% in dogs","volume":"23","author":"Lavy E","year":"2000","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"e_1_2_5_33_2","unstructured":"WeberDJ.A retrospective analysis of clindamycin dosage regimens in dogs. Upjohn Technical Report 1977; no. 7254\/77\/7261\/001: 17 November 1977."},{"key":"e_1_2_5_34_2","unstructured":"WeberDJ BarbiersAR HenkeCL.Clindamycin bioactivity following a multidose oral administration of Cleosin in dogs. Upjohn Technical Report 1978; no. 7254\/78\/7261\/002: 16 March 1978."},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2460\/ajvr.1992.53.12.2333","article-title":"Pharmacokinetics of clindamycin phosphate in dogs after single intravenous and intramuscular administrations","volume":"53","author":"Budsberg SC","year":"1992","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2004.01.022"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/jms.344"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.7.878"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600621016"},{"key":"e_1_2_5_40_2","first-page":"81","volume-title":"Antimicrobial Therapy in Veterinary Medicine","author":"Martinez M","year":"2006"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.630"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00024-9"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm476"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_5_45_2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.43.8.2005","article-title":"Evaluation of low\u2010dose, extended\u2010interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection","volume":"43","author":"Lewis RE","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1996.tb00088.x"},{"volume-title":"Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard\u2010Third Edition","year":"2007","author":"Clinical and Laboratory Standards Institute","key":"e_1_2_5_47_2"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2005.03.006"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3164.2011.00969.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3164.2011.00969.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:42:33Z","timestamp":1741106553000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3164.2011.00969.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1111\/j.1365-3164.2011.00969.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3164.2011.00969.x","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"type":"print","value":"0959-4493"},{"type":"electronic","value":"1365-3164"}],"subject":[],"published":{"date-parts":[[2011,3,21]]},"assertion":[{"value":"2011-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}